Skip to main content
. Author manuscript; available in PMC: 2023 May 21.
Published in final edited form as: Endocr Pract. 2022 Aug 11;28(10):923–1049. doi: 10.1016/j.eprac.2022.08.002

Table 18.

Recommended Steps for the Intensification of Insulin Therapy When Prandial Control Is Needed

Therapeutic option Insulin dose Notes/caveats
Step 1. Add prandial therapy: Begin with Step 1A for T2D and Step 1B for T1D
Step 1A: GLP-1 RA, SGLT2 inhibitor, or DPP-4 inhibitor If glucose goals remain unmet, add prandial insulin
Step 1B: Prandial insulin TDD 0.3 to 0.5 units/kg (50% basal; 50% prandial) Basal + prandial insulin analogs preferred over (NPH + regular insulin) or premixed insulin
Step 2. Monitor for hyperglycemia; Titrate insulin every 2–3 days to reach glycemic goalsa
Fixed regimen Increase TDD by 2 units/d
Adjustable regimen
 Elevated fasting BG Increase HS basal doses Increase dose by 10% to 20% depending on severity of BG elevation
 Elevated premidday meal BG Increase breakfast prandial insulin doses
 Elevated pre-evening meal BG Increase midday prandial insulin dose
 Elevated bedtime BG Increase dinner prandial insulin dose
Premixed insulin
 FBG/premeal BG >180 mg/dL Increase AM or PM dose depending on times of BG elevation Increase dose by 10% to 20% depending on severity of BG elevation
Step 3. Monitor for hypoglycemia
Adjustable regimen
Low fasting BG Reduce HS basal dose Decrease dose by 10% to 20% depending on severity of hypoglycemia
Low premidday meal BG Reduce breakfast prandial dose
Low pre-evening meal BG Reduce midday prandial dose
Low bedtime BG Reduce evening prandial dose
Premixed insulin
Low BGs in AM or PM Reduce AM or PM dose depending on times of BG elevation Reduce dose by 10% to 20% depending on severity of BG elevation

Abbreviations: A1C = hemoglobin A1c; AM = morning; BG = blood glucose; DPP-4 = dipeptidyl peptidase 4; FBG = fasting blood glucose; GLP-1 RA = glucagon-like peptide 1 receptor agonist; HS = at bedtime; NPH = Neutral Protamine Hagedorn; PM = evening; PPG = postprandial glucose; SGLT2 = sodium glucose cotransporter 2; T1D = type 1 diabetes; T2D = type 2 diabetes; TDD = total daily dose

a

For most persons with T2D taking insulin, glucose goals are A1C <7% and fasting and premeal blood glucose <110 mg/dL in the absence of hypoglycemia. A1C and FBG targets may be adjusted based on a person’s age, duration of diabetes, presence of comorbidities, diabetic complications, and hypoglycemia risk.